Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

[The overall assessment of the quality of the physical health of patients with multiple sclerosis after the application of physical therapy. Part 1].
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
Drugs@FDA
Rare onset symptoms in multiple sclerosis.
Treatment Burden and Chronic Illness: Who is at Most Risk?
Prevalence of people who could benefit from augmentative and alternative communication (AAC) in the UK: determining the need.
Multiple sclerosis: Could Helicobacter pylori provide protection against multiple sclerosis?
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
Measuring participation as defined by the World Health Organization in the International Classification of Functioning, Disability and Health. Psychometric properties of the Ghent Participation Scale.
Fumaric acid esters prevent the NLRP3 inflammasome-mediated and ATP-triggered pyroptosis of differentiated THP-1 cells.
Decreased systemic IL-7 and soluble IL-7Rα in multiple sclerosis patients.
Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis.
Voiding Dysfunction in Multiple Sclerosis.
Fumaric acid esters promote neuronal survival upon ischemic stress through activation of the Nrf2 but not HIF-1 signaling pathway.
The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Glial cells as drug targets: What does it take?
The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients.
Autoimmune myelopathies.
Intrathecal interferon reduces exacerbations of multiple sclerosis.
Induction of a Unique Isoform of the NCOA7 Oxidation Resistance Gene by Interferon β-1b.
Glatiramer Acetate Protects Against Inflammatory Synaptopathy in Experimental Autoimmune Encephalomyelitis.
CinnoVex home page
Rituximab for relapsing-remitting multiple sclerosis.
EMD Serono and Pfizer announce FDA approval of Rebif® Rebidose® (interferon beta-1a)
Differential transcriptional response profiles in human myeloid cell populations.

Pages